Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 9/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.40 |
| ▸ | CDK9 | P50750 | 3/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5020038 | 0.86 | GRM2 (0.54) | GRM2SLC6A3NTSR1HTR2ACCNT1 | |
| SCHEMBL5020012 | 0.80 | GRM2 (0.58) | GRM2SLC6A3NTSR1HTR2A | |
| SCHEMBL4566187 | 0.78 | GRM2 (0.53) | GRM2SLC6A3NTSR1CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL6195966 | 0.74 | MAPT (0.49) | GRM2SLC6A3NTSR1HTR2ACHRM4 | |
| SCHEMBL15236759 | 0.74 | GRM2 (0.53) | GRM2SLC6A3NTSR1CCNT1CDK9 | |
| SCHEMBL6926374 | 0.74 | CCNT1 (0.50) | GRM2SLC6A3HTR2ACCNT1CDK9 | |
| SCHEMBL749203 | 0.74 | GRM2 (1.00) | GRM2SLC6A3HTR2A | |
| SCHEMBL21231846 | 0.73 | SLC6A2 (0.54) | GRM2SLC6A3HTR2ACHRM4CHRM1 | |
| SCHEMBL748928 | 0.73 | GRM2 (1.00) | GRM2SLC6A3HTR2A | |
| SCHEMBL10322502 | 0.72 | GRM2 (0.78) | GRM2SLC6A3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2012062752-A1 | RADIOLABELLED mGLuR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | GRM2, GRM3, GRM1 | GRM2 1/4885SLC6A3 310/4885NTSR1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.